Transmissible spongiform encephalopathy future or investigational therapies
|
Transmissible spongiform encephalopathy Microchapters |
|
Differentiating Transmissible spongiform encephalopathy from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Transmissible spongiform encephalopathy future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Transmissible spongiform encephalopathy future or investigational therapies |
|
FDA on Transmissible spongiform encephalopathy future or investigational therapies |
|
CDC on Transmissible spongiform encephalopathy future or investigational therapies |
|
Transmissible spongiform encephalopathy future or investigational therapies in the news |
|
Blogs on Transmissible spongiform encephalopathy future or investigational therapies |
|
Directions to Hospitals Treating Transmissible spongiform encephalopathy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Future or Investigational Therapies
Recent research from the University of Toronto and Caprion Pharmaceuticals have discovered one possible avenue which might lead to quicker diagnosis, a vaccine or possibly even treatment for prion diseases. The abnormally folded proteins which cause the disease have been found to expose a side chain of amino acids which the properly folded protein does not expose. Antibodies specifically coded to this side chain amino acid sequence have been found to stimulate an immune response to the abnormal prions and leave the normal proteins intact. [2]
Another idea involves using custom peptide sequences. Since some research suggests prions aggregate by forming beta barrel structures, work done in vitro has shown that peptides made up of beta barrel-incompatible amino acids can help break up accumulations of prion. Yet a third idea concerns genetic therapy, whereby the gene for encoding protease-resistant protein is considered to be an error in several species, and therefore something to be inhibited.